Home > Healthcare > Medical Devices > Diagnostic Devices > Fecal Occult Testing Market

Fecal Occult Testing Market Size

Report ID: GMI6513
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Fecal Occult Testing Market Size

Fecal Occult Testing Market size was worth USD 1 billion in 2022 and is poised to record substantial growth at 5.3% CAGR from 2023-2032, driven by the increasing prevalence of rectal & colon cancer.

To get key market trends

Download Free Sample

Fecal occult testing, also referred to as fecal occult blood testing (FOBT), is a vital medical diagnostic procedure designed to identify minute quantities of concealed blood in stool samples. The existence of such concealed blood can serve as an indicative factor for various gastrointestinal (GI) conditions, encompassing colorectal cancer, polyps, ulcers, and other related disorders. This procedure involves the collection of a stool sample, followed by chemical reactions that reveal the presence of blood. Positive outcomes from this test lead to further diagnostic measures to pinpoint the underlying cause of the blood in the stool, thereby facilitating early detection and subsequent treatment.

Fecal Occult Testing Market Report Attributes
Report Attribute	Details
Base Year:	2022
Fecal Occult Testing Market Size in 2022:	USD 1 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	7.3%
2032 Value Projection:	USD 2 Billion
Historical Data for:	2018 to 2022
No. of Pages:	205
Tables, Charts & Figures:	270
Segments covered:	Test Type, End-use, and Region
Growth Drivers:	Increasing prevalence of rectal & colon cancer Growing government initiatives towards colorectal cancer Surge in point of care testing and non-invasive tests Technological advancements
Pitfalls & Challenges:	High cost of testing Lack of awareness regarding fecal occult testing

Learn more about the key segments shaping this market

Download Free Sample

The rising incidence of rectal and colon cancer is a significant driver for the market. Colorectal cancer is one of the most common cancers globally, and early detection plays a crucial role in improving patient outcomes. Fecal occult testing serves as a non-invasive and relatively simple method for detecting hidden traces of blood in the stool, which can be an early indicator of colorectal cancer. Furthermore, the growing preference for convenient and patient-friendly point-of-care testing (POCT) and non-invasive diagnostics has propelled fecal occult testing into prominence. Being non-invasive and easily conducted in clinics and primary care settings, fecal occult testing aligns perfectly with this trend. Its simple sample collection process and lack of specialized equipment needs make it ideal for point-of-care use. This upsurge in demand for non-invasive testing has consequently elevated fecal occult testing's adoption as a favored screening method.

Authors: Mariam Faizullabhoy , Pratiksha Kamthe

Frequently Asked Questions (FAQ) :

Fecal occult testing industry size reached USD 1 billion in 2022 and will witness 7.3% CAGR through 2032 due to the rising incidence of rectal and colon cancer worldwide.

The guaiac FOB stool test segment garnered USD 381.3 million in the fecal occult testing industry in 2022 on account of its established reputation in medical practice and historical integration into colorectal cancer screening programs.

U.S. fecal occult testing industry crossed USD 353.1 million in 2022 and is projected to expand significantly through 2032 owing to the highly advanced and well-established healthcare infrastructure in the region.

HUMASIS.COM, CTK Biotech, Inc., Biopanda Reagents Ltd, Biohit Oyj, CERTEST BIOTEC, Cenogenics Corporation, Alfa Scientific Designs, Inc., Siemens Healthcare GmbH, Jant Pharmacal Corporation., Quidel Corporation, and Wondfo are some of the fecal occult testing companies worldwide.